Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001558370-25-005332
Filing Date
2025-04-24
Accepted
2025-04-24 07:00:16
Documents
21
Period of Report
2025-06-05

Document Format Files

Seq Description Document Type Size
1 DEF 14A acrs-20250605xdef14a.htm   iXBRL DEF 14A 1261451
2 GRAPHIC acrs-20250605xdef14a_a001.jpg GRAPHIC 3610
3 GRAPHIC acrs-20250605xdef14a_a016.jpg GRAPHIC 35181
4 GRAPHIC acrs-20250605xdef14a_a017.jpg GRAPHIC 36367
5 GRAPHIC acrs-20250605xdef14a_bg001.jpg GRAPHIC 143671
6 GRAPHIC acrs-20250605xdef14a_bg002.jpg GRAPHIC 93798
  Complete submission text file 0001558370-25-005332.txt   3231194

Data Files

Seq Description Document Type Size
7 EX-101.SCH acrs-20250605.xsd EX-101.SCH 4595
8 EX-101.DEF acrs-20250605_def.xml EX-101.DEF 3846
9 EX-101.LAB acrs-20250605_lab.xml EX-101.LAB 6752
10 EX-101.PRE acrs-20250605_pre.xml EX-101.PRE 6061
23 EXTRACTED XBRL INSTANCE DOCUMENT acrs-20250605xdef14a_htm.xml XML 412032
Mailing Address 701 LEE ROAD SUITE 103 WAYNE PA 19087
Business Address 701 LEE ROAD SUITE 103 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

EIN.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37581 | Film No.: 25863523
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)